RedHill Biopharma (Israel) Financial Indicators Patterns

RDHL -- Israel Stock  

ILS 264.00  35.70  11.91%

We recommend you to use RedHill Biopharma fundamental analysis to see if markets are presently mispricing the firm. In other words this interface allows you to confirm available drivers of RedHill Biopharma as well as the relationship between them. . We found twenty-six available financial ratios for RedHill Biopharma which can be compared to its competitors. To make sure the equity is not overpriced, please check all RedHill Biopharma fundamentals including its Shares Outstanding, Revenue, EBITDA, as well as the relationship between Price to Sales and Gross Profit . Use RedHill Biopharma to protect against small markets fluctuations. The stock experiences very speculative upward sentiment.. Check odds of RedHill Biopharma to be traded at S250.8 in 30 days

RedHill Biopharma Company Summary

RedHill Biopharma competes with BioTime, Compugen Ltd, Clal Biotechnology, and Pluristem Therapeutics. RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. RedHill Biopharma operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 74 people.

RedHill Biopharma Total Asset vs Retained Earnings

RedHill Biopharma Ltd is rated fifth in total asset category among related companies. It is rated third in retained earnings category among related companies .

RedHill Biopharma Systematic Risk

The output start index for this execution was twelve with a total number of output elements of twenty-seven. The Beta measures systematic risk based on how returns on RedHill Biopharma correlated with the market. If Beta is less than 0 RedHill Biopharma generally moves in the opposite direction as compared to the market. If RedHill Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one RedHill Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of RedHill Biopharma is generally in the same direction as the market. If Beta > 1 RedHill Biopharma moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Distress Rating

RedHill Biopharma Financial Distress Probability

40%
Chance of Financial Distress
RedHill Biopharma Ltd has less than 40 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Compare RedHill Biopharma

Compare RedHill Biopharma To Peers

RedHill Biopharma Opportunity Range

December 9, 2018 Opportunity Range

Additionally take a look at Your Equity Center. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Search macroaxis.com